-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

Benzinga·04/10/2026 10:31:05
Listen to the news
Needham analyst Gil Blum initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.